back to US directory
us clinical guidance

Adult anxiety-disorder screening

USPSTF preventive-screening guidance for anxiety disorders in asymptomatic adults, including age limits and the required diagnostic follow-through.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Asymptomatic adults aged 19 years or older who do not have a diagnosed mental-health disorder and do not have recognized signs or symptoms of anxiety. The 2023 USPSTF statement addresses preventive screening only. It does not establish how to diagnose or treat generalized anxiety disorder, panic disorder or another condition in a person who is already symptomatic.
sources for this section:USPSTF anxiety 2023

The Bottom Line

  • The USPSTF recommends screening adults aged 19 through 64 for anxiety disorders, including people who are pregnant or postpartum.
  • For adults aged 65 years or older, the USPSTF concludes that current evidence is insufficient to assess the balance of benefits and harms of screening.
  • A positive screening result is not a diagnosis. The USPSTF states that positive results should receive further evaluation to determine whether an anxiety disorder is present.
  • The USPSTF found no evidence establishing an optimal screening interval. Repeated screening timing therefore is not prescribed by this source.
  • Screening should be implemented with systems that can provide diagnostic assessment, treatment and appropriate follow-up after a positive result.
sources for this section:USPSTF anxiety 2023

Practical clinical workflow

1
First confirm that the encounter concerns preventive screening in an adult without recognized anxiety symptoms or a known mental-health diagnosis; otherwise this USPSTF pathway is not the applicable clinical task.
2
Select a validated anxiety screening instrument appropriate to the adult population and care setting. A questionnaire result remains a screening result rather than a clinical diagnosis.
3
Review the completed result and arrange a separate diagnostic evaluation for a positive screen. This source does not specify the components of that diagnostic assessment.
4
Ensure that the practice has a route to evidence-based care and follow-up for people whose diagnostic evaluation confirms an anxiety disorder.
5
Do not assign a fixed rescreening schedule from this statement; the evidence reviewed by the USPSTF did not identify an optimal interval.
sources for this section:USPSTF anxiety 2023

Safety boundaries and escalation

  • Do not use this preventive statement as a symptom-assessment pathway. A person with recognized anxiety symptoms or another clinical concern falls outside the screened population described by the recommendation.
  • Do not use a positive questionnaire alone to label an anxiety disorder; the source explicitly requires additional diagnostic evaluation.
  • The insufficient-evidence statement for adults aged 65 years or older is not evidence that screening is harmful and is not a recommendation for or against assessment prompted by symptoms.
  • This source does not substantiate a medical-mimic work-up, psychotherapy sequence, medication choice, dose, monitoring plan, crisis pathway or panic-disorder treatment algorithm.
sources for this section:USPSTF anxiety 2023

Localization

This page reports the US Preventive Services Task Force recommendation: Grade B for adults through age 64, including pregnancy and postpartum, and an I statement from age 65. It is a preventive-services statement rather than a national anxiety-treatment guideline. Coverage, diagnostic services and behavioral-health access vary across US plans and settings.
sources for this section:USPSTF anxiety 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Preventive Services Task ForceAnxiety Disorders in Adults: ScreeningFinal Recommendation Statement; Grade B through age 64 and I statement from age 65 路 published 2023-06-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.